Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after

Bibliography

• Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477-90
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:277-300
   PubMed Web of Science ®Google Scholar
• Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000;27:177-86
   PubMed Web of Science ®Google Scholar
• Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999;353:14-17
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med 2001;345:1711-12
   PubMed Web of Science ®Google Scholar
• Yang JC, Childs R. Immunotherapy for renal cell cancer. J Clin Oncol 2006;24:5576-83
   PubMed Web of Science ®Google Scholar
• Klapper JA, Downey SG, Smith FO, High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008;113:293-301
   PubMed Web of Science ®Google Scholar
• Golumbek PT, Lazenby AJ, Levitsky HI, Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-16
   PubMed Web of Science ®Google Scholar
• Seki N, Brooks AD, Carter CR, Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol 2002;168:3484-92
   Google Scholar
• Finke JH, Rayman P, Edinger M, Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. J Immunother 1992;11:1-11
   PubMed Web of Science ®Google Scholar
• Bernhard H, Jager E, Maeurer MJ, Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes. Tissue Antigens 1996;48:22-31
   PubMed Web of Science ®Google Scholar
• Brouwenstijn N, Gaugler B, Kruse KM, Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Int J Cancer 1996;68:177-82
   PubMed Web of Science ®Google Scholar
• Jantzer P, Schendel DJ. Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. Cancer Res 1998;58:3078-86
   PubMed Web of Science ®Google Scholar
• Horowitz MM, Gale RP, Sondel PM, Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM, Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European group for blood and marrow transplantation working party chronic leukemia. Blood 1995;86:2041-50
   PubMed Web of Science ®Google Scholar
• Collins RH Jr, Shpilberg O, Drobyski WR, Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-44
   PubMed Web of Science ®Google Scholar
• Storb R. Allogeneic hematopoietic stem cell transplantation – yesterday, today, and tomorrow. Exp Hematol 2003;31:1-10
   PubMed Web of Science ®Google Scholar
• Childs R, Chernoff A, Contentin N, Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-8
   PubMed Web of Science ®Google Scholar
• Rini BI, Zimmerman T, Stadler WM, Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002;20:2017-24
   PubMed Web of Science ®Google Scholar
• Artz AS, Van Besien K, Zimmerman T, Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: the University of Chicago experience. Bone Marrow Transplant 2005;35:253-60
   PubMed Web of Science ®Google Scholar
• Ueno NT, Cheng YC, Rondon G, Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003;102:3829-36
   PubMed Web of Science ®Google Scholar
• Nakayama K, Tannir NM, Liu P, Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:975-85
   PubMed Web of Science ®Google Scholar
• Tykodi SS, Warren EH, Thompson JA, Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 2004;10:7799-811
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Barrier R, Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Biol Blood Marrow Transplant 2006;12:778-85
   PubMedGoogle Scholar
• Peres E, Abidi MH, Mellon-Reppen S, Reduced intensity transplantation for metastatic renal cell cancer with 2-year follow-up. J Immunother 2007;30:562-6
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Harashima N, Kajigaya S, Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest 2008;118:1099-109
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Da Prada GA, Giorgiani G, Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 2002;94:2409-15
   PubMed Web of Science ®Google Scholar
• Bregni M, Dodero A, Peccatori J, Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002;99:4234-6
   PubMed Web of Science ®Google Scholar
• Bregni M, Bernardi M, Servida P, Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. Bone Marrow Transplant 2009;44:237-42
   PubMed Web of Science ®Google Scholar
• Hentschke P, Barkholt L, Uzunel M, Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003;31:253-61
   PubMed Web of Science ®Google Scholar
• Blaise D, Bay JO, Faucher C, Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004;103:435-41
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Kami M, Hori A, Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up. Exp Hematol 2004;32:599-606
   PubMed Web of Science ®Google Scholar
• Massenkeil G, Roigas J, Nagy M, Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant 2004;34:309-16
   PubMed Web of Science ®Google Scholar
• Rzepecki P, Zolnierek J, Sarosiek T, Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma – single center experience. Neoplasma 2005;52:238-42
   PubMed Web of Science ®Google Scholar
• Busca A, Novarino A, de Fabritiis P, Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors. Hematology 2006;11:171-7
   PubMed Web of Science ®Google Scholar
• Barkholt L, Bregni M, Remberger M, Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol 2006;17:1134-40
   PubMed Web of Science ®Google Scholar
• Yun T, Lee KW, Song EG, Non-myeloablative allogeneic stem cell transplantation for metastatic renal cell carcinoma. Clin Transplant 2007;21:337-43
   PubMed Web of Science ®Google Scholar
• Ishiyama K, Takami A, Suzuki S, Relationship between tumor-infiltrating T lymphocytes and clinical response after reduced-intensity allogeneic hematopoietic stem cell transplantation for advanced renal cell carcinoma: a single center prospective study. Jpn J Clin Oncol 2009;39:807-12
   PubMed Web of Science ®Google Scholar
• Baron F, Storb R. Current roles for allogeneic hematopoietic cell transplantation following nonmyeloablative or reduced-intensity conditioning. Clin Adv Hematol Oncol 2005;3:799-819
   PubMedGoogle Scholar
• Ueno NT, Childs RW. What's past is prologue: lessons learned and the need for further development of allogeneic hematopoietic stem cell transplantation for renal cell carcinoma. Biol Blood Marrow Transplant 2007;13:31-3
   PubMed Web of Science ®Google Scholar
• Peccatori J, Barkholt L, Demirer T, Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer 2005;104:2099-103
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA, Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96
   PubMed Web of Science ®Google Scholar
• Mekhail TM, Abou-Jawde RM, Boumerhi G, Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-41
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Mariani T, Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20:2376-81
   PubMed Web of Science ®Google Scholar
• Upton MP, Parker RA, Youmans A, Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005;28:488-95
   PubMed Web of Science ®Google Scholar
• Harlin H, Artz AS, Mahowald M, Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells. Bone Marrow Transplant 2004;33:491-7
   PubMed Web of Science ®Google Scholar
• Takami A, Asakura H, Koshida K, Reduced-intensity allogeneic stem cell transplantation for renal cell carcinoma: in vivo evidence of a graft-versus-tumor effect. Haematologica 2004;89:375-6
   PubMedGoogle Scholar
• Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007;7:340-52
   PubMed Web of Science ®Google Scholar
• de Bueger M, Bakker A, Van Rood JJ, Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992;149:1788-94
   PubMed Web of Science ®Google Scholar
• Klein CA, Wilke M, Pool J, The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. J Exp Med 2002;196:359-68
   PubMed Web of Science ®Google Scholar
• Fujii N, Hiraki A, Ikeda K, Expression of minor histocompatibility antigen, HA-1, in solid tumor cells. Transplantation 2002;73:1137-41
   PubMed Web of Science ®Google Scholar
• Tykodi SS, Fujii N, Vigneron N, C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients. Clin Cancer Res 2008;14:5260-9
   PubMed Web of Science ®Google Scholar
• Overes IM, Levenga TH, Vos JC, Aberrant expression of the hematopoietic-restricted minor histocompatibility antigen LRH-1 on solid tumors results in efficient cytotoxic T cell-mediated lysis. Cancer Immunol Immunother 2009;58:429-39
   PubMed Web of Science ®Google Scholar
• Brickner AG, Warren EH, Caldwell JA, The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J Exp Med 2001;193:195-206
   PubMed Web of Science ®Google Scholar
• Warren EH, Vigneron NJ, Gavin MA, An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 2006;313:1444-7
   PubMed Web of Science ®Google Scholar
• Meunier MC, Delisle JS, Bergeron J, T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat Med 2005;11:1222-9
   PubMed Web of Science ®Google Scholar
• Dickinson AM, Wang XN, Sviland L, In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002;8:410-14
   PubMed Web of Science ®Google Scholar
• Akatsuka Y, Warren EH, Gooley TA, Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. Br J Haematol 2003;123:671-5
   PubMed Web of Science ®Google Scholar
• Hess Michelini R, Freschi M, Manzo T, Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors. Cancer Res 2010;70:3505-14
   Google Scholar
• Molldrem JJ, Lee PP, Wang C, Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000;6:1018-23
   PubMed Web of Science ®Google Scholar
• Middleton D, Menchaca L, Rood H, Komerofsky R. New allele frequency database. Available from: http://www.allelefrequencies.net. Tissue Antigens 2003;61:403-7
   PubMed Web of Science ®Google Scholar
• Spierings E, Hendriks M, Absi L, Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. PLoS Genet 2007;3:e103
   PubMed Web of Science ®Google Scholar
• Kausche S, Wehler T, Schnurer E, Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells. Cancer Res 2006;66:11447-54
   PubMed Web of Science ®Google Scholar
• Tykodi SS, Thompson JA, Sandmaier BM, Ex vivo isolation of RCC-reactive CD8+ CTL clones from HLA-identical allogeneic donor T cell lines stimulated by CD80-transfected tumor cells. J Clin Oncol 2007;25: abstract #15625
   Google Scholar
• Dorrschuck A, Schmidt A, Schnurer E, CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression. Blood 2004;104:2591-9
   PubMed Web of Science ®Google Scholar
• Mullally A, Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 2007;109:1355-62
   PubMed Web of Science ®Google Scholar
• Wenandy L, Kollgaard T, Letsch A, The 1170 A-P single-nucleotide polymorphism (SNP) in the Her-2/neu protein (HER2) as a minor histocompatibility antigen (mHag). Leukemia 2009;23:1926-9
   PubMed Web of Science ®Google Scholar
• de Martino M, Klatte T, Seligson DB, CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J Urol 2009;182:728-34
   PubMed Web of Science ®Google Scholar
• Vissers JL, De Vries IJ, Schreurs MW, The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 1999;59:5554-9
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J Clin Oncol 2010;28:1061-8
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-8
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56
   PubMed Web of Science ®Google Scholar
• Manning EA, Ullman JG, Leatherman JM, A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 2007;13:3951-9
   PubMed Web of Science ®Google Scholar
• Tykodi SS, Voong LN, Warren EH. Combining allogeneic immunotherapy with an mTOR inhibitor for advanced renal cell carcinoma. Bone Marrow Transplant 2010;45:1360-2
   PubMed Web of Science ®Google Scholar
• Armand P, Gannamaneni S, Kim HT, Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008;26:5767-74
   PubMed Web of Science ®Google Scholar
• Ljungman P, Bregni M, Brune M, Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010;45:219-34
   PubMed Web of Science ®Google Scholar
• Tykodi SS, Thompson JA. Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. Expert Opin Biol Ther 2008;8:1947-53
   PubMed Web of Science ®Google Scholar
• Tykodi SS, Satoh S, Harrop R, Warren EH. Cytolytic effects of CD8+ CTL clones specific for an HLA-A2 epitope from the 5T4 tumor antigen on tumor cells in vitro. J Clin Oncol 2010;28(Suppl): abstract e13142
   Google Scholar
• Uemura H, Fujimoto K, Tanaka M, A Phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 2006;12:1768-75
   PubMed Web of Science ®Google Scholar
• Wierecky J, Muller MR, Wirths S, Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006;66:5910-18
   PubMed Web of Science ®Google Scholar
• National Cancer Institute (NCI). Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer. ClinicalTrials.gov NCT00923845. Available from: http://clinicaltrials.gov/ct2/show/NCT00923845?term=NCT00923845&rank=1
   Google Scholar
• Bashey A, Medina B, Corringham S, CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009;113:1581-8
   PubMed Web of Science ®Google Scholar
• Yang JC, Hughes M, Kammula U, Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30:825-30
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute (NHLBI). Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer. ClinicalTrials.gov NCT00003553. Available from: http://clinicaltrials.gov/ct2/show/NCT00003553?term=NCT00003553&rank=1
   Google Scholar
• Baylor College of Medicine. Stem Cell Transplant for Hematologic Diseases and Renal Cell Cancer. ClinicalTrials.gov NCT00058825. Available from: http://clinicaltrials.gov/ct2/show/NCT00058825?term=NCT00058825&rank=1
   Google Scholar
• Masonic Cancer Center, University of Minnesota. Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy. ClinicalTrials.gov NCT00303719. Available from: http://clinicaltrials.gov/ct2/show/NCT00303719?term=NCT00303719&rank=1
   Google Scholar
• Federation Nationale des Centres de Lutte Contre le Cancer. Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer. ClinicalTrials.gov NCT00056095. Available from: http://clinicaltrials.gov/ct2/show/NCT00056095?term=NCT00056095&rank=1
   Google Scholar